| Recruiting | Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the Treatment of Relapsed or Re NCT07166419 | Ohio State University Comprehensive Cancer Center | Phase 1 |
| Recruiting | A Multicenter, Open-Label, Non-Randomized, Single-Arm Clinical Study of Nanobody CD5-CAR T Cell Therapy for Re NCT07070323 | Beijing GoBroad Hospital | Phase 1 / Phase 2 |
| Recruiting | CAR T CELL Therapy for Pediatric, Adolescent and Young Adult Patients With CD19-Positive Leukemia NCT06847269 | St. Jude Children's Research Hospital | Phase 2 |
| Recruiting | Humanized CD19-Specific CAR T Cells for the Treatment of Patients With Positive Relapsed or Refractory CD19 Po NCT06447987 | City of Hope Medical Center | Phase 1 |
| Not Yet Recruiting | Clinical Research of CD19 Targeted CAR-T Cell in Relapsed/ Refractory B-ALL NCT06641024 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Recruiting | Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for NCT06581081 | Peking University People's Hospital | N/A |
| Recruiting | CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies NCT06316856 | Beijing GoBroad Hospital | Phase 1 / Phase 2 |
| Recruiting | Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies NCT06316427 | Beijing GoBroad Hospital | Phase 1 / Phase 2 |
| Recruiting | A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL) NCT06287528 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Active Not Recruiting | A Study of Revumenib in Combination With Chemotherapy for Patients Diagnosed With Relapsed or Refractory Leuke NCT05761171 | Children's Oncology Group | Phase 2 |
| Unknown | ThisCART19A Bridging to alloHSCT for R/R B-ALL NCT05679687 | The First Affiliated Hospital of Soochow University | Phase 1 |
| Active Not Recruiting | Trial Treating Relapsed Acute Lymphoblastic Leukemia With Venetoclax and Navitoclax NCT05192889 | St. Jude Children's Research Hospital | Phase 1 / Phase 2 |
| Recruiting | Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lym NCT05418088 | Sumithira Vasu | Phase 1 |
| Completed | Phase II Study of Anti-CD19 CAR-T Cells Treating Leukemia Children NCT04325841 | Beijing Boren Hospital | Phase 2 |
| Recruiting | A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents NCT05334823 | Chongqing Precision Biotech Co., Ltd | Phase 2 |
| Completed | Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia NCT04996160 | Tanja Andrea Gruber | Phase 1 |
| Terminated | Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia NCT04526795 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | DS-1594b With or Without Azacitidine, Venetoclax, or Mini-HCVD for the Treatment of Relapsed or Refractory Acu NCT04752163 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Phase I Study of pCAR-19B in the Treatment of Adult CD19-positive Relapsed/Refractory B-ALL NCT04888442 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Withdrawn | Flotetuzumab in Treating Patients With Recurrent or Refractory CD123 Positive Blood Cancer NCT03739606 | City of Hope Medical Center | Phase 2 |
| Completed | Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in P NCT04139434 | Newave Pharmaceutical Inc | Phase 1 |
| Completed | Low Dose Daunorubicin in Pediatric Relapsed/Refractory Acute Leukemia NCT04562792 | Children's Mercy Hospital Kansas City | Phase 2 |
| Completed | Study of Anti-CD22 CAR-T Cells Treating Leukemia Children NCT04340167 | Beijing Boren Hospital | Phase 2 |
| Terminated | Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial NCT03878524 | OHSU Knight Cancer Institute | Phase 1 |
| Completed | Phase I Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolesce NCT04888468 | Chongqing Precision Biotech Co., Ltd | Phase 1 |
| Unknown | Personalized Targeted Preparative Regimen Before T-depleted Allogeneic HSCT in Children With Chemoresistent Ac NCT04000698 | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | Phase 3 |
| Active Not Recruiting | Pembrolizumab and Blinatumomab in Treating Participants With Recurrent or Refractory Acute Lymphoblastic Leuke NCT03512405 | City of Hope Medical Center | Phase 1 / Phase 2 |
| Recruiting | 211At-BC8-B10 Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory High-Ris NCT03670966 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Unknown | Study Evaluating the Efficacy and Safety With CD19CAR-T for Relapsed or Refractory Acute Lymphoblastic Leukemi NCT04012879 | Chinese PLA General Hospital | Phase 1 |
| Completed | Pevonedistat With VXLD Chemotherapy for Adolescent/Young Adults With Relapsed/Refractory ALL or Lymphoblastic NCT03349281 | Julio Barredo, MD | Phase 1 |
| Completed | Vyxeos(CPX-351) in Adults w R/R Acute Lymphoblastic Leukemia NCT03575325 | H. Lee Moffitt Cancer Center and Research Institute | Phase 2 |
| Active Not Recruiting | CART22 Alone or in Combination With huCART19 for ALL NCT03620058 | University of Pennsylvania | Phase 1 |
| Terminated | Venetoclax, Ponatinib, and Dexamethasone in Participants With Philadelphia Chromosome or BCR-ABL Positive Rela NCT03576547 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Terminated | EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acu NCT03519984 | University of Southern California | Phase 1 |
| Recruiting | HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After NCT03326921 | Fred Hutchinson Cancer Center | Phase 1 |
| Active Not Recruiting | Low-Intensity Chemotherapy, Ponatinib and Blinatumomab in Treating Patients With Philadelphia Chromosome-Posit NCT03147612 | M.D. Anderson Cancer Center | Phase 2 |
| Terminated | Inotuzumab Ozogamicin in Treating Patients With Relapsed or Refractory CD22 Positive Acute Lymphoblastic Leuke NCT03094611 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Blinatumomab, Methotrexate, Cytarabine, and Ponatinib in Treating Patients With Philadelphia Chromosome-Positi NCT03263572 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | 211^At-BC8-B10 Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, A NCT03128034 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Active Not Recruiting | Study of CD19/CD22 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults w/ Recurrent or Refrac NCT03241940 | Stanford University | Phase 1 |
| Completed | Umbilical Cord Blood Transplant With Added Sugar and Chemotherapy and Radiation Therapy in Treating Patients W NCT03096782 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lympho NCT03136146 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Palbociclib and Sorafenib, Decitabine, or Dexamethasone in Treating Patients With Recurrent or Refractory Leuk NCT03132454 | M.D. Anderson Cancer Center | Phase 1 |
| Recruiting | Personalized NK Cell Therapy in CBT NCT02727803 | M.D. Anderson Cancer Center | Phase 2 |
| Recruiting | ONC201 in Treating Patients With Relapsed or Refractory Acute Leukemia or High-Risk Myelodysplastic Syndrome NCT02392572 | M.D. Anderson Cancer Center | Phase 1 / Phase 2 |
| Completed | High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory NCT02551718 | University of Washington | N/A |
| Active Not Recruiting | Blinatumomab and Combination Chemotherapy or Dasatinib, Prednisone, and Blinatumomab in Treating Older Patient NCT02143414 | National Cancer Institute (NCI) | Phase 2 |
| Completed | Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Rela NCT02220985 | Fred Hutchinson Cancer Center | Phase 2 |
| Completed | Dose Adjusted EPOCH Regimen in Combination With Ofatumumab or Rituximab in Treating Patients With Newly Diagno NCT02199184 | M.D. Anderson Cancer Center | Phase 2 |
| Active Not Recruiting | Cellular Immunotherapy in Treating Patients With High-Risk Acute Lymphoblastic Leukemia NCT02146924 | City of Hope Medical Center | Phase 1 |
| Completed | Laboratory Treated T Cells in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Non- NCT01865617 | Fred Hutchinson Cancer Center | Phase 1 / Phase 2 |
| Unknown | NK Cells in Cord Blood Transplantation NCT01619761 | M.D. Anderson Cancer Center | Phase 1 |
| Terminated | Pilot Study Of Sirolimus Plus Multiagent Chemotherapy For Relapsed/Refractory Acute Lymphoblastic Leukemia/Lym NCT01658007 | Children's Hospital Medical Center, Cincinnati | EARLY_Phase 1 |
| Terminated | Targeted Therapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia or Acute Myelog NCT01620216 | OHSU Knight Cancer Institute | Phase 2 |